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Abstract 
Mantle cell lymphoma represents 2.5-7% all
of non Hodgkin’s lymphomas. Stomach is the
most  common  site  of  extranodal  lymphoma.
However, that is not the case with mantle cell
lymphoma, which is extremely rare. We pres-
ent a case of 71-year-old woman admitted to
the Internal Clinic of the University Clinical
Hospital  Center  Rijeka,  because  of  stomach
discomfort and melena. Endoscopy and com-
puted tomography revealed a polyp in gastric
antrum. Histopathologic, immunohistochemic
and genetic methods were also performed and
the results were consistent with primary gas-
tric mantle cell lymphoma without periepigas-
tric  and/or  local  or  distant  abdominal  lymph
node involvement.
Introduction
Primary  isolated  gastric  mantle  cell  lym-
phoma (MCL) is an extremely rare form of gas-
trointestinal tumour. It represents 2.5-7%1 of
all non-Hodgkin’s lymphomas. However, stom-
ach is the most comon site of extranodal lym-
phoma, which are almost all of B-cell lineage,
including extranodal marginal zone B-cell lym-
phomas of mucosa-associated lymphoid tissue
(MALT lymphoma) and diffuse large B-cell lym-
phomas (DLBC).2,3 Development of MCL is a
result  of  malignant  transformation  of  B-cell
lymphocytes in mantle zone of a lymph node
follicle  -  pregerminal  center  that  surrounds
normal germinal center follicles. This subtype
of non-Hodkin’s lymphoma is also caracterized
by  the  chromosomal  translocation  t(11;14)
(q13;q32).3,4 Specific result of this transloca-
tion  is  an  overexpression  of  the  cyclin  D1
(CCND1), which is normally not expressed in
B lymphocytes, who have a very important rolle
in cell cycle regulation. Furthermore, immuno-
histochemical  phenotype  CD5+,  CD19+,
CD20+,  CD10-,  CD23-,  FMC-7+,  bcl-2+ and
cyclin D1+ is specific of MCL.2-6 We however
need to emphasize that aberrant immunophe-
notype  was  also  established  in  several
cases.4,7-8 Although nowadays we do have pow-
erful genetic, immunohistocemical and other
modern diagnostic and therapeutic methods,
MCL still presents itself as a very aggressive
disease with poor prognosis and median sur-
vival of 3-4 years.1
The first case of isolated primary MCL has
been published in 2004.9 Since then very few
case reports have been reported and published,
and those that were usually were secondary
gastric  involvements  from  nodal  mantle  cell
lymphoma (MCL) or lymphomas in the course
of  primary  intestinal  MCL  (lymphomatous
polyposis). 
We present a case of gastric MCL in a patient
without  other  gastrointestinal  comorbidities
and without personal history of significant ill-
nessess (except mild arterial hypertension).
Case Report
A  71-year-old,  previously  healthy  female
patient was admitted at the Internal Clinic of
the University Clinical Hospital Center Rijeka,
because  of  persistent  stomach  discomfort
(lasting for 5 months) and melena. Her med-
ical records showed that she had been previ-
ously diagnosed only with mild arterial hyper-
tension and had no gastrointestinal symptoms.
Physical examination revealed an overweight,
pale,  cardiorespiratory  compensated  patient
without any palpable peripheral lymph nodes,
no liver or spleen enlargement or any patholog-
ic abdominal mass. However, the patient com-
plained of slight discomfort during the palpa-
tion of the epigastric region.
Laboratory analyses showed anemia due to
iron deficiency (Hemoglobin 94 g/L, MCV 81 fL,
MCHC 318 g/L, Fe 3 umol/L, UIBC 62 umol/L,
feritin 16 ug/L), with slightly elevated ESR (38
mm/h). Leukocyte total count was normal (4,2
¥109/L) with proportional leukocyte differen-
tial count. Platelets (357¥109/L) and coagula-
tion  tests  were  in  normal  range  as  well  as
other  biochemical  analyses  (proteinogram,
CRP and LDH). 
Gastroscopy  (Figure  1)  and  computerized
tomography (Figure 2) identified a large ulcer-
ated tumor with polypoid surface in the gastric
antrum,  with  no  apparent  local  lymph  node
involvement. 
Histological analysis of tissue taken by gas-
tric biopsy revealed a dense atypical lymphoid
infiltrate composed of small to medium sized
cells with slightly irregular nuclear contours.
Immunohistochemically, cells were positive for
CD20, CD5, CD79a, CD43 and cyclin D1, but
negative for CD3, and bcl-6 (Figure 3). 
Fluorescent  in  situ hybridization  studies
showed  the  presence  of  the  chromosomal
translocation  t(11;14)(q13;q32),  which  is
characteristic  for  MCL.  Extensive  clinical
staging  was  performed  but  no  further  evi-
dence  of  lymphoma  was  established
(colonoscopy;  computerized  tomography  of
thorax,  abdomen  and  pelvis;  bone  marrow
analysis). Following chemotherapy (8 cycle R-
CHOP)  the  patient  is  disease  free  at  12
months after diagnosis, confirmed by PET/CT
immaging and gastroscopy.
Discussion
We present a case where MCL is not associ-
ated with any other gastrointestinal patholog-
ical condition. However, we took into consid-
eration  comorbidities  often  associated  with
appearance  of  MCL.  MCL  is  more  likely  to
appear along with other gastrointestinal dis-
eases (Chron’s disease, adenocarcinoma).1,2,9
In the vast majority of cases, gastrointestinal
lymphoma can be diagnosed with endoscopic
biopsy. By using additional immunological and
molecular markers we can group lymphomas
into subtypes according to the WHO classifica-
tion and that is the cornerstone for further
decision making. We retrospectively reviewed
clinical  features,  including  involved  organs,
histopathologic  examination,  immunohisto-
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chemic and genetic methods. We also estab-
lished  Cyclin  D1  overexpression  and  per-
formed  immunohistochemic  methods  (cells
were  positive  for  CD20,  CD5,  CD79a,  CD43
and  negative  for  CD3)  which  finally  confir-
mated the diagnosis of gastric MCL.
Primary  gastrointestinal  mantle  cell  lym-
phomas are very uncommon and they rarely
involve stomach. Contrary to that, stomach is
the most common site of primary extranodal
lymphoma, although almost all cases are of B-
cell lineage. Isolated primary gastric localiza-
tion is extremely rare. All that being said, man-
tle cell lymphoma is a specific type of malig-
nant lymphoma that has been reported mostly
through case reports.1,9Therefore, the fact that
there are only few reported cases limits our
understanding  of  primary  mantle  cell  lym-
phoma from a clinical and therapeutic view-
point. 
Treatment of MCL is nowhere near satisfac-
tory  and  there  are  no  proven  and  standard
regimes used in therapy. Standard therapy by
alkylating  agents  (with  or  without  corticos-
teroids)  offers  substantial  palliation  but  no
real  cure  and  treatment  therefore  fails  in
majority of cases. Effective treatment of gastric
MCL still remains a very controversial issue
with very poor response rates.10-12
Conclusions
Primary  isolated  gastric  mantle  cell  lym-
phoma (MCL) is an extremely rare form of gas-
trointestinal  tumour.  Stomach  is  the  most
common site of extranodal lymphoma. To our
knowledge,  only  few  authors  described  the
appearance  of  a  primary  gastric  mantle  cell
lymphoma.  However,  in  those  cases  tumor
occurence was associated with other gastroin-
testinal diseases. Therefore, the fact that there
are only few reported cases limits our under-
standing  of  primary  mantle  cell  lymphoma
from a clinical and therapeutic viewpoint. We
present a case where MCL was not associated
with  any  other  gastrointestinal  pathological
condition,  even  though  Chron’s  disease  and
adenocarcinoma  were  taken  into  considera-
tion.  Current  experiences  with  treatment  of
MCL are very poor and there are no proven and
standard  regimes  used  in  therapy.  Effective
treatment of gastric MCL still remains a very
controversial  issue  with  very  poor  response
rates. Therefore, mantle cell lymphoma has a
very poor prognosis. In the light of everything
said,  one  should  always  consider  a  primary
mantle  cell  lymphoma  if  a  solitary  gastroin-
testinal polypoid tumor is discovered, especial-
ly  if  no  other  gastrointestinal  diseases  are
present.
Case Report
Figure 1. Gastroscopy - tumor presence in
the gastric antrum.
Figure  2.  Computerized  tomography.
Diffuse  wall  thickening  of  the  gastric
antrum, which is in direct contact with the
wall  of  duodenum  and  suppresses  pan-
creas.
Figure 3. Histological picture of gastric mantle-cell lymphom. Magnification x 40. A)
tumor cells show nodular and diffuse infiltration of gastric mucosa; B), C) and D) tumor
cells are positive for CD20, ciklinD1 and CD5 antigen; E) and F) tumor cells are negative
for CD3 and bcl-6. [Hematology Reports 2012; 4:e1]
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